Triptorelin 3mg Therapy- 28 day

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	HSE approved reimbursement status*
Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.	C61	00489a	N/A

* This applies to post 2012 indications

TREATMENT:

Triptorelin 3mg is administered once every 28 days until disease progression or unacceptable toxicity develops.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	Triptorelin	3mg	IM	n/a	Every 28 days

ELIGIBILITY:

- Indication as above

CAUTION:

- History of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval
- As sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases

EXCLUSIONS:

- Hypersensitivity to triptorelin or any of the excipients

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant with expertise in the treatment of prostate carcinoma.

TESTS:

Baseline tests:

- FBC, renal and liver profile
- Bone profile
- Blood glucose

Regular tests:

- FBC, renal and liver profile as clinically indicated
- Blood glucose and bone profile as clinically indicated

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens

Disease monitoring:
Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- No recommended dose modifications.

Table 1: Dose modification of triptorelin in renal and hepatic impairment

Renal Impairment	Hepatic Impairment
No dose modification necessary	No dose modification necessary
Recommendations as per SPC previously agreed NCCP regimens	

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Triptorelin: Minimal **(Refer to local policy)**

PREMEDICATIONS: None

OTHER SUPPORTIVE CARE: Calcium and vitamin D supplementation **(Refer to local policy)**

ADVERSE EFFECTS:

- Please refer to the relevant Summary of Product Characteristics (SmPC) for details.

DRUG INTERACTIONS:

- Current SmPC and drug interaction databases should be consulted for information.

REFERENCES:

1. Triptorelin (DECAPEPTYL®) Summary of Product Characteristics. Last updated: 28/03/2025.Accessed May 2025. Available at: https://assets.hpra.ie/products/Human/31847/Licence_PPA0465-261-001_27032025162402.pdf

Version	Date	Amendment	Approved By
1	30/05/2018		Prof Maccon Keane
2	27/05/2020	Reviewed.	Prof Maccon Keane
3	14/07/2025	Reviewed. Updated in line with NCCP standardisation.	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPSACTregimens